Viridian Therapeutics
VRDN
136 hedge funds and large institutions have $1.24B invested in Viridian Therapeutics in 2024 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 62 increasing their positions, 36 reducing their positions, and 19 closing their positions.
72% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 36
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
3% more funds holding
Funds holding: 132 → 136 (+4)
2.2% less ownership
Funds ownership: 115.36% → 113.16% (-2.2%)
6% less capital invested
Capital invested by funds: $1.32B → $1.24B (-$77.5M)
50% less funds holding in top 10
Funds holding in top 10: 10 → 5 (-5)
54% less call options, than puts
Call options by funds: $2.88M | Put options by funds: $6.23M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$37.4M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$34.5M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$25.9M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$21.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
-$21.8M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$11.8M |
| 3 |
Morgan Stanley
New York
|
-$9.45M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$9.19M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
-$7.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Walleye Trading
New York
| – | -$362K | -16,602 | Closed |
|
|
LP
152
LMR Partners
London,
United Kingdom
| – | -$218K | -10,000 | Closed |
|
153
Simplex Trading
Chicago,
Illinois
| – | -$55.4K | -2,856 | Closed |
|
154
Group One Trading
Chicago,
Illinois
| – | -$330 | -17 | Closed |
|
|
C
155
Covestor
London,
United Kingdom
| – | -$19 | -1 | -20% |
|
VRDN Hedge Fund Activity: Q1 2024 in Review
136 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q1 2024, worth a combined $1.24B — down 5.9% from $1.32B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new VRDN positions and 19 closed out — a net gain of 4 holders — while 62 added to existing stakes and 36 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $37.4M. The largest seller was Vestal Point Capital, exiting entirely with an estimated $21.8M sold.
- 136 institutional investors held Viridian Therapeutics (VRDN) as of Q1 2024, up from 132 in Q4 2023.
- Funds reported $1.24B of Viridian Therapeutics stock for Q1 2024, down 5.9% quarter-over-quarter.
- 23 funds opened new Viridian Therapeutics positions in Q1 2024 and 19 closed out, a net change of +4 holders.
- The largest Viridian Therapeutics buyer in Q1 2024 was Perceptive Advisors, an estimated $37.4M added.
- The largest Viridian Therapeutics seller in Q1 2024 was Vestal Point Capital, an estimated $21.8M sold.
Based on aggregated 13F filings for Q1 2024.